Systematic analysis of drug combinations against Gram-positive bacteria.


Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 23 12 2022
accepted: 30 08 2023
medline: 8 11 2023
pubmed: 29 9 2023
entrez: 28 9 2023
Statut: ppublish

Résumé

Drug combinations can expand options for antibacterial therapies but have not been systematically tested in Gram-positive species. We profiled ~8,000 combinations of 65 antibacterial drugs against the model species Bacillus subtilis and two prominent pathogens, Staphylococcus aureus and Streptococcus pneumoniae. Thereby, we recapitulated previously known drug interactions, but also identified ten times more novel interactions in the pathogen S. aureus, including 150 synergies. We showed that two synergies were equally effective against multidrug-resistant S. aureus clinical isolates in vitro and in vivo. Interactions were largely species-specific and synergies were distinct from those of Gram-negative species, owing to cell surface and drug uptake differences. We also tested 2,728 combinations of 44 commonly prescribed non-antibiotic drugs with 62 drugs with antibacterial activity against S. aureus and identified numerous antagonisms that might compromise the efficacy of antimicrobial therapies. We identified even more synergies and showed that the anti-aggregant ticagrelor synergized with cationic antibiotics by modifying the surface charge of S. aureus. All data can be browsed in an interactive interface ( https://apps.embl.de/combact/ ).

Identifiants

pubmed: 37770760
doi: 10.1038/s41564-023-01486-9
pii: 10.1038/s41564-023-01486-9
pmc: PMC10627819
doi:

Substances chimiques

Anti-Bacterial Agents 0
Drug Combinations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2196-2212

Subventions

Organisme : European Molecular Biology Laboratory (EMBL Heidelberg)
ID : Internal budget
Organisme : Joint Programming Initiative on Antimicrobial Resistance (Joint Programming Initiative for Antimicrobial Resistance)
ID : Disrupt
Organisme : Joint Programming Initiative on Antimicrobial Resistance (Joint Programming Initiative for Antimicrobial Resistance)
ID : Combinatorials

Informations de copyright

© 2023. The Author(s).

Références

Eliopoulos, G. M. & Moellering, R. C. Jr. in Antibiotics in Laboratory Medicine 4th edn (ed. Lorian, V.) 330–396 (Williams & Wilkins, 1996).
Murray, C. J. L. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
doi: 10.1016/S0140-6736(21)02724-0
Cook, M. A. & Wright, G. D. The past, present, and future of antibiotics. Sci. Transl. Med. 14, eabo7793 (2022).
pubmed: 35947678 doi: 10.1126/scitranslmed.abo7793
Tyers, M. & Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17, 141–155 (2019).
pubmed: 30683887 doi: 10.1038/s41579-018-0141-x
Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348–350 (2011).
pubmed: 21516114 doi: 10.1038/nchembio.559
Taylor, P. L., Rossi, L., De Pascale, G. & Wright, G. D. A forward chemical screen identifies antibiotic adjuvants in Escherichia coli. ACS Chem. Biol. 7, 1547–1555 (2012).
pubmed: 22698393 doi: 10.1021/cb300269g
Farha, M. A., Verschoor, C. P., Bowdish, D. & Brown, E. D. Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. Chem. Biol. 20, 1168–1178 (2013).
pubmed: 23972939 doi: 10.1016/j.chembiol.2013.07.006
Farha, M. A. et al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams. ACS Chem. Biol. 8, 226–233 (2013).
pubmed: 23062620 doi: 10.1021/cb300413m
Campbell, J. et al. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus. ACS Chem. Biol. 6, 106–116 (2011).
pubmed: 20961110 doi: 10.1021/cb100269f
Lázár, V., Snitser, O., Barkan, D. & Kishony, R. Antibiotic combinations reduce Staphylococcus aureus clearance. Nature 610, 540–546 (2022).
pubmed: 36198788 pmcid: 9533972 doi: 10.1038/s41586-022-05260-5
Brochado, A. R. et al. Species-specific activity of antibacterial drug combinations. Nature 559, 259–263 (2018).
pubmed: 29973719 pmcid: 6219701 doi: 10.1038/s41586-018-0278-9
Jawetz, E. & Gunnison, J. B. Studies on antibiotic synergism and antagonism: a scheme of combined antibiotic action. Antibiot. Chemother. 2, 243–248 (1952).
Roemhild, R., Bollenbach, T. & Andersson, D. I. The physiology and genetics of bacterial responses to antibiotic combinations. Nat. Rev. Microbiol. 20, 478–490 (2022).
pubmed: 35241807 doi: 10.1038/s41579-022-00700-5
Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T. & Giovannucci, E. L. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 314, 1818–1831 (2015).
pubmed: 26529160 pmcid: 4752169 doi: 10.1001/jama.2015.13766
National Health and Nutrition Examination Survey Data (CDC, NCHS, 2021); https://wwwn.cdc.gov/nchs/nhanes/2017-2018/p_rxq_rx.htm
Pai, M. P., Momary, K. M. & Rodvold, K. A. Antibiotic drug interactions. Med. Clin. North Am. 90, 1223–1255 (2006).
pubmed: 17116445 doi: 10.1016/j.mcna.2006.06.008
Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327 (2018).
pubmed: 29276051 doi: 10.1016/S1473-3099(17)30753-3
Farha, M. A. et al. Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase. Proc. Natl Acad. Sci. USA 112, 11048–11053 (2015).
pubmed: 26283394 pmcid: 4568241 doi: 10.1073/pnas.1511751112
Bliss, C. I. The toxicity of poisons applied jointly1. Ann. Appl. Biol. 26, 585–615 (1939).
doi: 10.1111/j.1744-7348.1939.tb06990.x
Loewe, S. & Muischnek, H. Über Kombinationswirkungen. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 114, 313–326 (1926).
doi: 10.1007/BF01952257
Vlot, A. H. C., Aniceto, N., Menden, M. P., Ulrich-Merzenich, G. & Bender, A. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls. Drug Discov. Today 24, 2286–2298 (2019).
pubmed: 31518641 doi: 10.1016/j.drudis.2019.09.002
Gilvary, C., Dry, J. R. & Elemento, O. Multi-task learning predicts drug combination synergy in cells and in the clinic. Preprint at bioRxiv https://doi.org/10.1101/576017 (2019).
Jawetz, E. The use of combinations of antimicrobial drugs. Annu. Rev. Pharmacol. 8, 151–170 (1968).
pubmed: 4875390 doi: 10.1146/annurev.pa.08.040168.001055
Mende, D. R., Sunagawa, S., Zeller, G. & Bork, P. Accurate and universal delineation of prokaryotic species. Nat. Methods 10, 881–884 (2013).
pubmed: 23892899 doi: 10.1038/nmeth.2575
Dillon, N. et al. Surprising synergy of dual translation inhibition vs. Acinetobacter baumannii and other multidrug-resistant bacterial pathogens. EBioMedicine 46, 193–201 (2019).
pubmed: 31353294 pmcid: 6711115 doi: 10.1016/j.ebiom.2019.07.041
Bollenbach, T., Quan, S., Chait, R. & Kishony, R. Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 139, 707–718 (2009).
pubmed: 19914165 pmcid: 2838386 doi: 10.1016/j.cell.2009.10.025
Tang, H.-J. et al. Cephalosporin-glycopeptide combinations for use against clinical methicillin-resistant Staphylococcus aureus isolates: enhanced in vitro antibacterial activity. Front. Microbiol. 8, 884 (2017).
pubmed: 28572795 pmcid: 5435797 doi: 10.3389/fmicb.2017.00884
Lai, C.-C., Chen, C.-C., Chuang, Y.-C. & Tang, H.-J. Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. Sci. Rep. 7, 41758 (2017).
pubmed: 28139739 pmcid: 5282487 doi: 10.1038/srep41758
Rieg, S. et al. Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia—a post hoc analysis in 964 prospectively evaluated patients. Clin. Microbiol. Infect. 23, 406.e1–406.e8 (2017).
pubmed: 27615722 doi: 10.1016/j.cmi.2016.08.026
Leone, S., Noviello, S. & Esposito, S. Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci. Infection 44, 273–281 (2016).
pubmed: 26324294 doi: 10.1007/s15010-015-0836-0
Baddour, L. M. et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. 170, 440–444 (2004).
pubmed: 15184200 doi: 10.1164/rccm.200311-1578OC
Habib, G. et al. 2015 ESC guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur. Heart J. 36, 3075–3128 (2015).
pubmed: 26320109 doi: 10.1093/eurheartj/ehv319
Bartash, R. & Nori, P. Beta-lactam combination therapy for the treatment of Staphylococcus aureus and Enterococcus species bacteremia: a summary and appraisal of the evidence. Int. J. Infect. Dis. 63, 7–12 (2017).
pubmed: 28789974 doi: 10.1016/j.ijid.2017.07.019
Ida, T. et al. Antagonism between aminoglycosides and beta-lactams in a methicillin-resistant Staphylococcus aureus isolate involves induction of an aminoglycoside-modifying enzyme. Antimicrob. Agents Chemother. 46, 1516–1521 (2002).
pubmed: 11959590 pmcid: 127169 doi: 10.1128/AAC.46.5.1516-1521.2002
Vakulenko, S. B. & Mobashery, S. Versatility of aminoglycosides and prospects for their future. Clin. Microbiol. Rev. 16, 430–450 (2003).
pubmed: 12857776 pmcid: 164221 doi: 10.1128/CMR.16.3.430-450.2003
Paul, M., Lador, A., Grozinsky-Glasberg, S. & Leibovici, L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. 2014, CD003344 (2014).
pubmed: 24395715 pmcid: 6517128
Typas, A. & Sourjik, V. Bacterial protein networks: properties and functions. Nat. Rev. Microbiol. 13, 559–572 (2015).
pubmed: 26256789 doi: 10.1038/nrmicro3508
Kavčič, B., Tkačik, G. & Bollenbach, T. Mechanisms of drug interactions between translation-inhibiting antibiotics. Nat. Commun. 11, 4013 (2020).
pubmed: 32782250 pmcid: 7421507 doi: 10.1038/s41467-020-17734-z
Sampson, B. A., Misra, R. & Benson, S. A. Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics 122, 491–501 (1989).
pubmed: 2547691 pmcid: 1203724 doi: 10.1093/genetics/122.3.491
Ruiz, N., Falcone, B., Kahne, D. & Silhavy, T. J. Chemical conditionality: a genetic strategy to probe organelle assembly. Cell 121, 307–317 (2005).
pubmed: 15851036 doi: 10.1016/j.cell.2005.02.014
Sauvage, E., Kerff, F., Terrak, M., Ayala, J. A. & Charlier, P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol. Rev. 32, 234–258 (2008).
pubmed: 18266856 doi: 10.1111/j.1574-6976.2008.00105.x
Egan, A. J. F., Errington, J. & Vollmer, W. Regulation of peptidoglycan synthesis and remodelling. Nat. Rev. Microbiol. 18, 446–460 (2020).
pubmed: 32424210 doi: 10.1038/s41579-020-0366-3
Lehár, J. et al. Chemical combination effects predict connectivity in biological systems. Mol. Syst. Biol. 3, 80 (2007).
pubmed: 17332758 pmcid: 1828746 doi: 10.1038/msb4100116
Schulz, M., Iwersen-Bergmann, S., Andresen, H. & Schmoldt, A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit. Care 16, R136 (2012).
pubmed: 22835221 pmcid: 3580721 doi: 10.1186/cc11441
Kavanaugh, M. L. & Jerman, J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception 97, 14–21 (2018).
pubmed: 29038071 doi: 10.1016/j.contraception.2017.10.003
Chan, E. W. L., Yee, Z. Y., Raja, I. & Yap, J. K. Y. Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin-resistant Staphylococcus aureus. J. Glob. Antimicrob. Resist. 10, 70–74 (2017).
pubmed: 28673701 doi: 10.1016/j.jgar.2017.03.012
Zimmermann, P. & Curtis, N. The effect of aspirin on antibiotic susceptibility. Expert Opin. Ther. Targets 22, 967–972 (2018).
Cohen, S. P., Levy, S. B., Foulds, J. & Rosner, J. L. Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway. J. Bacteriol. 175, 7856–7862 (1993).
pubmed: 7504664 pmcid: 206962 doi: 10.1128/jb.175.24.7856-7862.1993
Price, C. T., Lee, I. R. & Gustafson, J. E. The effects of salicylate on bacteria. Int. J. Biochem. Cell Biol. 32, 1029–1043 (2000).
pubmed: 11091136 doi: 10.1016/S1357-2725(00)00042-X
Husted, S. & van Giezen, J. J. J. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc. Ther. 27, 259–274 (2009).
pubmed: 19604248 doi: 10.1111/j.1755-5922.2009.00096.x
Storey, R. F. et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 25, 517–525 (2014).
pubmed: 24127651 doi: 10.3109/09537104.2013.842965
Sexton, T. R. et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl. Sci. 3, 435–449 (2018).
pubmed: 30175268 pmcid: 6115703 doi: 10.1016/j.jacbts.2018.05.005
Sun, J. et al. Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear Staphylococcus aureus bacteremia. Sci. Transl. Med. 13, eabd6737 (2021).
pubmed: 33762439 pmcid: 9121309 doi: 10.1126/scitranslmed.abd6737
Ulloa, E. R., Uchiyama, S., Gillespie, R., Nizet, V. & Sakoulas, G. Ticagrelor increases platelet-mediated Staphylococcus aureus killing, resulting in clearance of bacteremia. J. Infect. Dis. 224, 1566–1569 (2021).
pubmed: 33966075 pmcid: 8599881 doi: 10.1093/infdis/jiab146
Lancellotti, P. et al. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant Gram-positive bacteria. JAMA Cardiol. 4, 596–599 (2019).
pubmed: 31066863 pmcid: 6506905 doi: 10.1001/jamacardio.2019.1189
Becher, I. et al. Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat. Nat. Chem. Biol. 12, 908–910 (2016).
pubmed: 27669419 doi: 10.1038/nchembio.2185
Mateus, A. et al. Thermal proteome profiling in bacteria: probing protein state in vivo. Mol. Syst. Biol. 14, e8242 (2018).
pubmed: 29980614 pmcid: 6056769 doi: 10.15252/msb.20188242
Mateus, A. et al. Thermal proteome profiling for interrogating protein interactions. Mol. Syst. Biol. 16, e9232 (2020).
pubmed: 32133759 pmcid: 7057112 doi: 10.15252/msb.20199232
Cheng, A. G. et al. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog. 6, e1001036 (2010).
pubmed: 20700445 pmcid: 2916881 doi: 10.1371/journal.ppat.1001036
Taber, H. W., Mueller, J. P., Miller, P. F. & Arrow, A. S. Bacterial uptake of aminoglycoside antibiotics. Microbiol. Rev. 51, 439–457 (1987).
pubmed: 3325794 pmcid: 373126 doi: 10.1128/mr.51.4.439-457.1987
Wood, B. M., Santa Maria, J. P. Jr, Matano, L. M., Vickery, C. R. & Walker, S. A partial reconstitution implicates DltD in catalyzing lipoteichoic acid d-alanylation. J. Biol. Chem. 293, 17985–17996 (2018).
pubmed: 30237166 pmcid: 6240853 doi: 10.1074/jbc.RA118.004561
Xia, G., Kohler, T. & Peschel, A. The wall teichoic acid and lipoteichoic acid polymers of Staphylococcus aureus. Int. J. Med. Microbiol. 300, 148–154 (2010).
pubmed: 19896895 doi: 10.1016/j.ijmm.2009.10.001
Pasquina, L. et al. A synthetic lethal approach for compound and target identification in Staphylococcus aureus. Nat. Chem. Biol. 12, 40–45 (2016).
pubmed: 26619249 doi: 10.1038/nchembio.1967
Brown, S., Santa Maria, J. P. Jr & Walker, S. Wall teichoic acids of Gram-positive bacteria. Annu. Rev. Microbiol. 67, 313–336 (2013).
pubmed: 24024634 doi: 10.1146/annurev-micro-092412-155620
Sastry, S. & Doi, Y. Fosfomycin: resurgence of an old companion. J. Infect. Chemother. 22, 273–280 (2016).
pubmed: 26923259 pmcid: 4833629 doi: 10.1016/j.jiac.2016.01.010
Ericsson, C. D., DuPont, H. L., Okhuysen, P. C., Jiang, Z.-D. & DuPont, M. W. Loperamide plus azithromycin more effectively treats travelers’ diarrhea in Mexico than azithromycin alone. J. Travel Med. 14, 312–319 (2007).
pubmed: 17883462 doi: 10.1111/j.1708-8305.2007.00144.x
Miró-Canturri, A., Ayerbe-Algaba, R. & Smani, Y. Drug repurposing for the treatment of bacterial and fungal infections. Front. Microbiol. 10, 41 (2019).
pubmed: 30745898 pmcid: 6360151 doi: 10.3389/fmicb.2019.00041
Phanchana, M. et al. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile. Sci. Rep. 10, 6497 (2020).
pubmed: 32300130 pmcid: 7162883 doi: 10.1038/s41598-020-63199-x
Maier, L. et al. Unravelling the collateral damage of antibiotics on gut bacteria. Nature https://doi.org/10.1038/s41586-021-03986-2 (2021).
Kunst, F. et al. The complete genome sequence of the Gram-positive bacterium Bacillus subtilis. Nature 390, 249–256 (1997).
pubmed: 9384377 doi: 10.1038/36786
Slager, J., Aprianto, R. & Veening, J.-W. Deep genome annotation of the opportunistic human pathogen Streptococcus pneumoniae D39. Nucleic Acids Res. 46, 9971–9989 (2018).
pubmed: 30107613 pmcid: 6212727
Baba, T., Bae, T., Schneewind, O., Takeuchi, F. & Hiramatsu, K. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. J. Bacteriol. 190, 300–310 (2008).
pubmed: 17951380 doi: 10.1128/JB.01000-07
Shiroma, A. et al. First complete genome sequences of Staphylococcus aureus subsp. aureus Rosenbach 1884 (DSM 20231T), determined by PacBio single-molecule real-time technology. Genome Announc. 3, e00800–e00815 (2015).
pubmed: 26184947 pmcid: 4505135 doi: 10.1128/genomeA.00800-15
Martin, B., García, P., Castanié, M.-P. & Claverys, J.-P. The recA gene of Streptococcus pneumoniae is part of a competence-induced operon and controls lysogenic induction. Mol. Microbiol. 15, 367–379 (1995).
pubmed: 7538190 doi: 10.1111/j.1365-2958.1995.tb02250.x
Reed, P. et al. Staphylococcus aureus survives with a minimal peptidoglycan synthesis machine but sacrifices virulence and antibiotic resistance. PLoS Pathog. 11, e1004891 (2015).
pubmed: 25951442 pmcid: 4423922 doi: 10.1371/journal.ppat.1004891
Stamsås, G. A. et al. CozEa and CozEb play overlapping and essential roles in controlling cell division in Staphylococcus aureus. Mol. Microbiol. 109, 615–632 (2018).
pubmed: 29884993 doi: 10.1111/mmi.13999
Huber, P. J. Robust estimation of a location parameter. Ann. Math. Stat. 35, 73–101 (1964).
doi: 10.1214/aoms/1177703732
Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-response analysis using R. PLoS ONE 10, e0146021 (2015).
pubmed: 26717316 doi: 10.1371/journal.pone.0146021
Baranyi, J. & Roberts, T. A. A dynamic approach to predicting bacterial growth in food. Int. J. Food Microbiol. 23, 277–294 (1994).
pubmed: 7873331 doi: 10.1016/0168-1605(94)90157-0
Goldoni, M. & Johansson, C. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol. In Vitro 21, 759–769 (2007).
pubmed: 17420112 doi: 10.1016/j.tiv.2007.03.003
R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2021).
RStudio Team. RStudio: Integrated Development Environment for R (RStudio, 2021).
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658 pmcid: 403769 doi: 10.1101/gr.1239303
Van der Borght, K. et al. BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism. Sci. Rep. 7, 17935 (2017).
pubmed: 29263342 pmcid: 5738392 doi: 10.1038/s41598-017-18068-5
Grassberger, P. On generalized Schürmann entropy estimators. Entropy 24, 680 (2022).
pubmed: 35626564 pmcid: 9141067 doi: 10.3390/e24050680
Bajusz, D., Rácz, A. & Héberger, K. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J. Cheminform. 7, 20 (2015).
pubmed: 26052348 pmcid: 4456712 doi: 10.1186/s13321-015-0069-3
Morgan, H. L. The generation of a unique machine description for chemical structures—a technique developed at Chemical Abstracts Service. J. Chem. Doc. 5, 107–113 (1965).
doi: 10.1021/c160017a018
Milanese, A. et al. Microbial abundance, activity and population genomic profiling with mOTUs2. Nat. Commun. 10, 1014 (2019).
pubmed: 30833550 pmcid: 6399450 doi: 10.1038/s41467-019-08844-4
Rognes, T., Flouri, T., Nichols, B., Quince, C. & Mahé, F. VSEARCH: a versatile open source tool for metagenomics. PeerJ 4, e2584 (2016).
pubmed: 27781170 pmcid: 5075697 doi: 10.7717/peerj.2584
Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792–1797 (2004).
pubmed: 15034147 doi: 10.1093/nar/gkh340
Guindon, S. et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307–321 (2010).
pubmed: 20525638 doi: 10.1093/sysbio/syq010
Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 10, 1567–1593 (2015).
pubmed: 26379230 doi: 10.1038/nprot.2015.101
Kurzawa, N., Franken, H., Anders, S., Huber, W. & Savitski, M. TPP2D: Detection of Ligand-protein Interactions from 2D Thermal Profiles (DLPTP). R package v.1.4.1 (2020).
Kurzawa, N. et al. Computational analysis of ligand dose range thermal proteome profiles. Nat. Commun. 11, 5783 (2020).
Kurzawa, N. et al. A computational method for detection of ligand-binding proteins from dose range thermal proteome profiles. Nat. Commun. 11, 5783 (2020).
pubmed: 33188197 pmcid: 7666118 doi: 10.1038/s41467-020-19529-8
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
pubmed: 10592173 pmcid: 102409 doi: 10.1093/nar/28.1.27
Tenenbaum, D. & Maintainer B. KEGGREST: Client-side REST Access to the Kyoto Encyclopedia of Genes and Genomes (KEGG). R package v.1.34.0 (2021).
Geistlinger, L., Csaba, G. & Zimmer, R. Bioconductor’s EnrichmentBrowser: seamless navigation through combined results of set- & network-based enrichment analysis. BMC Bioinformatics 17, 45 (2016).
pubmed: 26791995 pmcid: 4721010 doi: 10.1186/s12859-016-0884-1
Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).
pubmed: 34557778 pmcid: 8454663
Radlinski, L. C. et al. Chemical induction of aminoglycoside uptake overcomes antibiotic tolerance and resistance in Staphylococcus aureus. Cell Chem. Biol. 26, 1355–1364.e4 (2019).
pubmed: 31402316 pmcid: 6800641 doi: 10.1016/j.chembiol.2019.07.009
Brötz-Oesterhelt, H. & Vorbach, A. Reprogramming of the caseinolytic protease by ADEP antibiotics: molecular mechanism, cellular consequences, therapeutic potential. Front. Mol. Biosci. 8, 690902 (2021).
pubmed: 34109219 pmcid: 8182300 doi: 10.3389/fmolb.2021.690902
Weinandy, F. et al. A β-lactone-based antivirulence drug ameliorates Staphylococcus aureus skin infections in mice. ChemMedChem 9, 710–713 (2014).
pubmed: 24678014 doi: 10.1002/cmdc.201300325

Auteurs

Elisabetta Cacace (E)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

Vladislav Kim (V)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
Collaboration for joint PhD degree between EMBL and Heidelberg University, Faculty of Biosciences, Heidelberg, Germany.

Vallo Varik (V)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

Michael Knopp (M)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

Manuela Tietgen (M)

Goethe University Frankfurt, University Hospital, Institute for Medical Microbiology and Infection Control, Frankfurt am Main, Germany.

Amber Brauer-Nikonow (A)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

Kemal Inecik (K)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

André Mateus (A)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

Alessio Milanese (A)

European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, Germany.
Department of Biology, Institute of Microbiology, and Swiss Institute of Bioinformatics, ETH Zurich, Zurich, Switzerland.

Marita Torrissen Mårli (MT)

Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.

Karin Mitosch (K)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

Joel Selkrig (J)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
Institute of Medical Microbiology, University Hospital of RWTH, Aachen, Germany.

Ana Rita Brochado (AR)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
Cluster of Excellence EXC 2124 Controlling Microbes to Fight Infections, University of Tübingen, Tübingen, Germany.
Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, Tübingen, Germany.

Oscar P Kuipers (OP)

Department of Molecular Genetics, Groningen Molecular Biology and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.

Morten Kjos (M)

Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.

Georg Zeller (G)

European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, Germany.

Mikhail M Savitski (MM)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

Stephan Göttig (S)

Goethe University Frankfurt, University Hospital, Institute for Medical Microbiology and Infection Control, Frankfurt am Main, Germany.

Wolfgang Huber (W)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.

Athanasios Typas (A)

European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany. typas@embl.de.
European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, Germany. typas@embl.de.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Humans China Cerebral Hemorrhage Patient Care Bundles Length of Stay

Classifications MeSH